Invitrogen Corporation (IVGN) Signs Definitive Agreement To Acquire BioSource International, Inc. (BIOI); Deal Strengthens Proteomics Franchise And Positions The Company To Enter New Markets; $130 Million
10/19/2005 5:09:00 PM
CARLSBAD, Calif.--(BUSINESS WIRE)--July 26, 2005--Invitrogen Corporation (Nasdaq:IVGN) today announced the signing of a definitive agreement to acquire publicly held life sciences company BioSource International (Nasdaq:BIOI) in an all-cash transaction totaling approximately $130 million. The transaction is subject to customary closing conditions, including regulatory approval and the approval of BioSource stockholders. The transaction is expected to close by the end of the year.
This deal augments Invitrogen's growing collection of protein and primary antibody products gained through its recent acquisitions of Zymed Laboratories and Caltag Laboratories. Additionally, it bolsters Invitrogen's offerings in both kinase and cytokine assay technologies for research applications and provides the company an opportunity to enter new markets in immunology, oncology and neurodegenerative disease.
comments powered by